Acadia Pharmaceuticals
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressin...
Latest News
7 days ago · businesswire.com
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent AppealSAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delaware's May 2025 decision upholding Acadia's U.S. Patent No. 11,452,721 (the ‘721 patent), which covers the NUPLAZID® (pimavanserin) 34 mg capsule formulation. “We continue to believe in the strength of our position on the NUPLAZID formulation patent, on which t.
12 days ago · seekingalpha.com
Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call TranscriptAcadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue EstimatesAcadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.26 per share a year ago.
12 days ago · marketbeat.com
What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings CallACADIA Pharmaceuticals NASDAQ: ACAD reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and Parkinson's disease psychosis drug NUPLAZID drove growth.
20 days ago · zacks.com
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to DeclineAcadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 month ago · zacks.com
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
2 months ago · zacks.com
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.
2 months ago · businesswire.com
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled “Methods and Compositions for Treatment of Rett Syndrome.” The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability, and the patent is expected to issue following completion of standard administrative.
2 months ago · zacks.com
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary GoalAcadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.
2 months ago · seekingalpha.com
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis TranscriptACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ACAD